News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Welichem Biotech Inc. (WBI.V) Announces IND-Enabling Toxicology Studies for its Lead Drug, WBI-1001


4/20/2009 11:30:08 AM

BURNABY, BC, April 20 /CNW/ - Welichem Biotech Inc. announces the start of GLP toxicology studies for its lead, anti-inflammatory drug WBI-1001. The long-term toxicology studies that are currently underway are designed to support the filing of an Investigational New Drug (IND) application for WBI-1001 with the U.S. FDA so as to initiate Phase II/III clinical studies in the US. Welichem intends to submit an IND for WBI-1001 in the Fall of 2009, following successful completion of the toxicology program.

Read at Canada NewsWire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES